

Defining Biomarker-Guided Immuno-Oncology Treatments

Fira Gran Via • Barcelona, Spain
Tarragona Auditorium, Hall 7

CHAIR

Roy S. Herbst

Ensign Professor of Medicine
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for
Translational Research
Director, Yale Center for
Immuno-Oncology (interim)
Yale Comprehensive Cancer
Center
Yale School of Medicine
New Haven, Connecticut, USA

FACULTY

Noemi Reguart

Consultant, Thoracic Oncology
Medical Oncology Department
Hospital Clinic, IDIBAPS
University of Barcelona
Barcelona, Spain

Federico Rojo

Head of Pathology Department
Scientific Director of Biobank
Hospital Universitario
Fundacion Jimenez Diaz
Madrid, Spain

Gilad Vainer

Department of Pathology
Hadassah-Hebrew University
Medical Center
Jerusalem, Israel

Wilko Weichert

Full Professor and Chairman
Institute of Pathology
Technical University Munich
(TUM)
Munich, Germany

Monday, 30 September 2019

18:30 – 20:00

Chair: Roy Herbst (USA)

AGENDA

18:30 – 18:40	Welcome and Introduction Biomarker-Driven Patient Management in Immuno-Oncology: An Overarching View <i>Roy Herbst</i>
18:40 – 19:10	PD-L1: From Controversial to Foundational Biomarker in Immuno-Oncology Treatment <i>Wilko Weichert, Gilad Vainer</i>
19:10 – 19:25	New Horizon for Biomarkers: What Is Now and Next? <i>Roy Herbst</i>
19:25 – 19:50	Experiences With Precision Medicine in Immuno-Oncology – Panel Discussion <i>Federico Rojo, Noemi Reguart</i>
19:50 – 20:00	Q&A <i>Roy Herbst</i>

Satellite Symposium Sponsored by MSD

